CereVasc has opened a new manufacturing and research facility in Wilmington, Massachusetts, US, as the company prepares for potential commercialisation of its investigational eShunt System.
The move follows two recent milestones: the completion of patient enrolment in the pivotal STRIDE clinical trial and the close of an $85m Series C funding round.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Located near Boston, the facility is intended to support assembly, inspection, testing, and manufacturing activities for the eShunt system.
The device is undergoing investigation as a minimally invasive alternative to conventional shunt surgery for communicating hydrocephalus, including normal pressure hydrocephalus (NPH).
CereVasc’s new site is designed to accommodate anticipated commercial and operational requirements, including workforce growth.
The company’s employment expansion is supported by a tax incentive from the Massachusetts Life Sciences Center, linked to job creation in the region.
CereVasc chairman and CEO Dan Levangie said: “This facility is an investment in CereVasc’s future.
“It expands the capabilities we’ll need as we prepare for potential commercialisation of the eShunt system, supports our long-term growth and helps position us to bring this innovation to patients.
“We’re proud to continue building CereVasc in Massachusetts, where the life sciences community continues to fuel innovation.”
The STRIDE clinical trial is intended to form the basis of the company’s expected Premarket Approval submission to the US Food and Drug Administration (FDA).
The eShunt system uses a percutaneous transvenous-transdural approach and includes an endovascular, implantable cerebrospinal fluid shunt with delivery components.
The device remains investigational and has not been approved by regulators in the US or elsewhere; its safety and effectiveness have not yet been established.
In June 2026, CereVasc concluded patient enrolment in its STRIDE pivotal study, assessing the safety and effectiveness of the investigational eShunt System for normal pressure hydrocephalus (NPH).
